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Background: Previous studies have documented an undertreatment of vascular risk factors, and patients with symptomatic
peripheral arterial disease (PAD) are at increased risk of recurrent vascular events. We examined which baseline variables
are related to future vascular events, investigated the course of vascular risk factors, and compared the number of vascular
risk factors at baseline and at follow-up to determine whether risk factor management could be further improved.
Methods: This study involved 461 patients with Fontaine classification II to IV who were enrolled in the SMART study
(Second Manifestations of ARTerial disease) from September 1996 to December 2000. Patients underwent a standard-
ized screening program for risk factors and were invited for a follow-up measurement during September 2003 to March
2005, after a mean follow-up of 5.5 years (SD, 1.3 years). In the interim period between baseline and follow-up
measurement, patients received usual care. During follow-up, vascular events (mortality, ischemic stroke, and myocardial
infarction) and PAD-related events (vascular surgery, interventions, and amputations) were documented in detail.
Results: In 2739 person-years of follow-up, 91 vascular events occurred, resulting in a 29.1% (95% confidence interval
[CI], 22.8%-35.4%) cumulative incidence proportion of recurrent vascular events. Older age, increased homocysteine
levels, impaired renal function, and a history of coronary heart disease at baseline were related to an increased risk of new
vascular events. Of the 461 patients, 108 patients died, 20 patients were lost to follow-up, and 333 patients were eligible
for follow-up measurement, in which 221 (66%) patients wished to participate. In 8 of the 221 patients, a nonfatal
vascular event occurred during follow-up. The prevalence of hypertension increased from 51% to 70% (95% CI,
10%-28%), the prevalence of obesity increased from 54% to 67% (95%CI, 3%-21%), and the prevalence of diabetes mellitus
increased from 8% to 16% (95% CI, 2%-14%). At follow-up, fewer patients were current smokers (59% to 37%; 95% CI,
13% to 31%), and fewer patients had increased lipid levels (96% to 73%; 95% CI, 29% to 16%). Medication use
increased in all drug categories during follow-up.
Conclusions: Age, increased homocysteine levels, impaired renal function, and a history of coronary heart disease were
independent risk factors for vascular events in patients with symptomatic PAD. The prevalence of most risk factors, except
for smoking and hyperlipidemia, increased over a 5.5-year period even though medication use increased over the same
period. (J Vasc Surg 2007;45:47-54.)The first clinical sign of peripheral arterial disease
(PAD) is usually intermittent claudication (IC), which af-
fects 2% to 3% ofmen and 1% to 2% of women older than 60
years in primary care settings.1 The frequency of IC in-
creases dramatically with advancing age, ranging from 0.6%
in individuals aged 45 to 54 years to 8.8% in patients aged
65 to 74 years.2 Progression to severe ischemia or amputa-
tion is unusual in patients with IC, occurring in approxi-
mately 1.4% of patients per year.3 IC not only limits func-
tional capacity and adversely affects quality of life, but also
is associated with a threefold to sixfold increased risk of
coronary heart disease (CHD) and stroke and a threefold to
fivefold increased risk of death due to cardiovascular disease
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doi:10.1016/j.jvs.2006.09.015(CVD) compared with patients without PAD.4 Patients
with multivessel PAD have a particularly poor long-term
prognosis, with a 15-fold increased risk of cardiovascular
mortality after 10 years compared with patients without
PAD.4 Although patients with PAD have a lower cumula-
tive occurrence of nonfatal vascular events compared with
patients with stroke or myocardial infarction (MI; 6.5% vs
11.8% and 8.5%), they experience the highest fatality due to
stroke, MI, or other vascular causes (24% vs 6% in patients
with stroke vs 7% in patients with MI) after 3 years.5
The aim of treatment in patients with symptomatic
PAD is to relieve lower extremity symptoms by interven-
tions such as regular exercise, endovascular therapy, or
surgery and to reduce the risk of generalized atherosclerosis
by treatment of risk factors.2 Risk modification to minimize
the risk of vascular morbidity and mortality requires major
changes in lifestyle and behavior and drug therapy, such as
smoking cessation and medical treatment with antithrom-
botic, lipid-lowering, and blood pressure–lowering agents,
which should be continued lifelong. There is clear evidence
that a combination of long-term, tailored medical treat-
ment provides effective secondary prevention.6-11 Yet de-
spite the proven benefits, patients with symptomatic PAD
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emia and antiplatelet therapy less often than patients with
CHD or cerebrovascular disease.12-14
The purpose of this study was threefold: (1) to deter-
mine which patient characteristics were related to the oc-
currence of fatal and nonfatal vascular events in patients
with symptomatic PAD to specify determinants of increas-
ing risk of recurrent vascular events, (2) to investigate the
course of risk factors to evaluate the change of risk factors in
patients who attended a vascular screening at baseline and
after a mean follow-up of 5.5 years, and (3) to determine
the difference in risk factors between follow-up and base-
line according to treatment goals for the different risk
factors according to the European Guidelines of Cardiovas-
cular Disease Prevention15 in order to determine whether
risk factor management could be further improved in pa-
tients with symptomatic PAD.
METHODS
Study population. Most patients with typical symp-
toms of IC (cramping pain in the lower legs during exer-
cise) or with rest pain, nonhealing ulcers, or gangrene were
referred by general practitioners (GPs) of the province
Utrecht to the outpatient clinic of the Department of
Vascular Surgery at the University Medical Center Utrecht,
The Netherlands. If the vascular surgeon diagnosed IC
(typical symptoms and a resting ankle-brachial pressure
index [ABI] 0.90), patients were asked to participate in
the SMART study (Second Manifestations of ARTerial
disease). The SMART study runs in parallel to the care
given by the vascular surgeon for PAD; decisions on revas-
cularization procedures were independently made by the
vascular surgeon. The SMART study is an ongoing single-
center prospective cohort study with the purpose of inves-
tigating the prevalence and incidence of additional vascular
disease in patients who already have a manifestation of
arterial disease or who are otherwise at high risk (diabetes
mellitus, hypertension, or hyperlipidemia) of developing
symptomatic arterial disease. The rationale and the study
design have been described previously.16 Briefly, patients
aged 18 to 79 years who were willing to participate and
gave their written informed consent underwent a standard-
ized vascular screening including a health questionnaire,
laboratory assessment, and ultrasonography. The ethics
committee of our institution approved the study. For this
study, the data of 461 consecutive patients with symptom-
atic PAD who were included in the vascular screening
program from September 1996 to December 2000 were
used. Patients were invited to visit the hospital again for a
follow-up measurement from September 2003 to March
2005. Patients received usual care from a GP or a vascular
specialist in the period between baseline and follow-up
measurement.
Vascular screening. Participating patients visited the
hospital after an overnight fast of at least 8 hours and
underwent the same screening at baseline and at follow-up.
Patients completed a health questionnaire on history and
symptoms of CVD, current medication use, and atheroscle-rotic risk factors (diabetes mellitus, hypertension, hyperlip-
idemia, smoking, diet, physical activity, and familial vascu-
lar history). The items on CHD and PAD were based on
the Rose Questionnaire.17 The severity of PAD was classi-
fied according to the Fontaine classification.18 Height and
weight were measured without shoes and heavy clothing.
Bodymass index (BMI) was calculated as weight divided by
height squared. Waist circumference was measured halfway
between the lower limb and the iliac crest. Blood pressure
was measured two times in the sitting position on the right
and left upper armwith a nonrandom sphygmomanometer.
Fasting blood was sampled to determine serum glucose,
total cholesterol, high-density lipoprotein (HDL) choles-
terol, triglycerides, creatinine, and homocysteine concen-
trations. Low-density lipoprotein (LDL) cholesterol was
calculated with Friedewald’s formula. An early-morning
urine sample was collected to measure albumin and creati-
nine concentrations. Resting ABI was measured for each
leg by taking the ratios of the highest systolic blood pres-
sure measured at the ankle to the highest systolic blood
pressure in both arms with the patient in the supine posi-
tion. The systolic blood pressure in the posterior tibial and
dorsal pedal arteries (left and right) was measured with an
8-MHz continuous-wave Doppler probe connected to an
IMEXLAB 9000 Vascular Diagnostic System (Imex Med-
ical Systems Inc, Golden, Colo), and that in both brachial
arteries was measured with a semiautomatic oscillometric
device (Omega 1400; Invivo Research Laboratories Inc,
Broken Arrow, Okla). The results of the vascular screening
were discussed at weekly meetings of a multidisciplinary
team consisting of an internist, vascular surgeon, cardiolo-
gist, vascular nurse practitioner, and, on request, a neurol-
ogist. An internist evaluated the results of the follow-up
measurement. If risk factors were not within the target
range, treatment was given according to the European
Guidelines of Cardiovascular Disease Prevention.15 The
vascular screening results and treatment recommendations
were reported in writing to the treating vascular specialist
(most often the vascular surgeon) and the GP, and further
action was left to their discretion. The patients were in-
formed by telephone about the results of the follow-up
measurement.
Difference in risk factors. One of our aims was to
quantify how risk factors changed over time. Therefore, we
determined the prevalence of hypertension, hyperlipid-
emia, diabetes mellitus, obesity, and smoking at baseline
and at follow-up. The cutoffs for the different risk factors
were according to the European Guidelines15 and were as
follows: hypertension, blood pressure greater than 140/90
mm Hg; hyperlipidemia, total cholesterol greater than 4.5
mmol/L or LDL cholesterol greater than 2.5 mmol/L;
diabetes mellitus, patients taking glucose-lowering agents;
obesity, BMI greater than 25 kg/m2; and current smoking.
The change in the number of risk factors was calculated by
subtracting the number of risk factors at follow-up from the
number at baseline.
Follow-up. Patients were biannually asked to com-
plete a questionnaire on hospitalizations and outpatient
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research nurse phoned the patient, family, or GP to obtain
the health status. The end point of interest for this study
was a composite of first occurrence of vascular events:
namely, mortality, ischemic stroke, and MI. Definitions of
events are given in Table I. PAD-related amputation, sur-
gical procedures (bypass), and percutaneous transluminal
angioplasty were also recorded during follow-up. If a pa-
tient or family recorded such an event, we retrieved hospital
discharge letters and the results of relevant laboratory and
radiology examinations. Three members of the SMART
Study Endpoint Committee independently audited all
events on the basis of available information. This commit-
tee consisted of physicians from different departments. In
case of disagreement, consensus was reached by consulting
other members of the Endpoint Committee. The patients
were followed up until they died or refused further partic-
ipation.
Data analysis. Data are presented as means with stan-
dard deviations or as percentages. Cox proportional haz-
ards analysis was used to assess the effect of risk factors on
Table I. Definitions of fatal and nonfatal events
Event Definition
Vascular death Sudden death: unexpected cardiac death
occurring within 1 h after onset of
symptoms or within 24 h given
convincing circumstantial evidence
Death from ischemic stroke
Death from intracerebral hemorrhage
(hemorrhage on CT scan)
Death from congestive heart failure
Death from myocardial infarction
Death from rupture of abdominal aortic
aneurysm
Vascular death from other cause, such as
sepsis after stent placement
Ischemic stroke Definite: relevant clinical features that
have caused an increase in impairment
of at least one grade on the modified
Rankin scale, accompanied by a fresh
ischemic infarction on a repeat brain
scan
Probable: clinical features that have
caused an increase in impairment of at
least one grade on the modified
Rankin scale, without a fresh ischemic
infarction on a repeat brain scan
Myocardial infarction Fatal or nonfatal myocardial infarction:
at least two of the following criteria:
1. Chest pain for at least 20 min, not
disappearing after administration of
nitrates
2. ST elevation 1 mm in two
following leads or a left bundle
branch block on the ECG
3. CK elevation of at least two times the
normal value of CK and an MB
fraction 5% of the total CK
CT, Computed tomography; ECG, electrocardiogram; CK, creatinine ki-
nase; MB, myocardial band.vascular events, and results are presented as hazard ratiosand 95% confidence intervals (CIs). If a patient had multi-
ple events, the first was used in the analysis. In model 1, the
age-adjusted association between baseline risk factors and
vascular events was examined. Additional adjustments for
systolic and diastolic blood pressure, smoking, HDL cho-
lesterol, and diabetes were made in model 2.
Differences between participants and those who re-
fused to participate at follow-up measurement were tested
with 2 tests (categorical variables), unpaired t tests (con-
tinuous normally distributed variables), or Mann-Whitney
U tests (continuous skewed variables). Changes in the
proportion of patients in whom risk factor values were
higher than the relevant cutoff level were determined and
reported with the corresponding 95% CIs. Calculations
were performed with SPSS version 12.0.1 (SPSS, Chicago,
Ill).
RESULTS
Study population. Patients were screened for the first
time between September 1996 and December 2000. Base-
line characteristics of the study population are given in
Table II. The 461 patients with symptomatic PAD had a
mean age of 60.2 years and were predominantly male
(68%). Eighty-seven percent of the patients were classified
as having Fontaine II and 13% as Fontaine III/IV, and the
mean ABI value of the 461 patients was 0.82.
Fatal and nonfatal events during follow-up. During
Table II. Baseline characteristics of the patients with
symptomatic peripheral arterial disease (n  461)
Age (y) 60.2  10.9
Male sex (%) 68
Body mass index (kg/m2) 25.7  3.9
Systolic blood pressure (mm Hg) 147  22
Diastolic blood pressure (mm Hg) 80  11
Total cholesterol (mmol/L) 5.9  1.2
Glucose (mmol/L) 6.5  2.2
Homocysteine (mol/L) 15.0  9.0
Creatinine clearance (Cockroft) (mL/min) 74  23
Hypertension* (%) 60
Diabetes mellitus type 2† (%) 14
Current smokers (%) 58
Ankle-brachial pressure index 0.82  0.2
Medication use
Antiplatelet agents (%) 53
Blood pressure–lowering agents (%) 46
Lipid-lowering agents (%) 25
ACE inhibitor and/or AIIA (%) 21
Fontaine classification
II (%) 87
III  IV (%) 13
Previous cardiovascular disease‡
Abdominal aortic aneurysm (%) 7
Cerebrovascular disease (%) 12
Coronary heart disease (%) 27
ACE, angiotensin-converting enzyme; AIIA, angiotensin II-antagonist.
Data are mean (SD) or %.
*Systolic blood pressure 140 mm Hg or diastolic blood pressure 90
mm Hg.
†Patients taking glucose-lowering agents.
‡Not mutually exclusive.follow-up (until September 1, 2004), 108 (23%) of the 461
sity li
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those who died was 66.9 years (SD, 9.7 years). Twenty-
seven (6%) of the 461 patients experienced an ischemic
stroke, and 57 (12%) of the 461 patients had an MI. The
composite of ischemic stroke, MI, or vascular death oc-
curred in 91 patients. There were 2739 person-years of
follow-up. The cumulative incidence proportion was 29.1%
(95% CI, 22.8%-35.4%) for the composite of subsequent
vascular events, 22.1% (95% CI, 16.4%-27.8%) for vascular
death, and 19.6% (95% CI, 13.9%-25.3%) for MI.
Amputation occurred in 38 legs of 35 patients during
follow-up. Surgical procedures (bypass or endarterectomy)
were performed the first time in 97 (21%) of the 461 patients
involving the aorta/iliac, iliac, or femoral/popliteal arteries.
Reoperations occurred most often (n 30) in the femoral/
popliteal segment and occurred in two patients at the iliac
artery segment. Percutaneous transluminal angioplasty was
performed the first time in 61 (13%) of the 461 patients, 32
times in the iliac segment, and 29 times in the femoral/
popliteal segment. Endovascular reinterventions occurred
five times in treated iliac arteries and three times in femoral/
popliteal arteries.
Older age, increased homocysteine levels, impaired re-
nal function, and a history of CHD (age adjusted) were
associated with an increased risk of fatal or nonfatal vascular
events (Table III).Male sex and decreasedHDL levels were
borderline significantly related to vascular events. The
strengths of the relations for a first vascular event remained
essentially the same after adjustment for classical risk factors
(data not shown). By analyzing the data separately for each
single event outcome, we found results in the same direc-
tion but based on a rather small number of events.
Follow-up measurement. At the follow-up visit, 108
(23%) of the 461 patients had died, and 20 (4%) patients
Table III. Hazard ratios and 95% CI of baseline character
Variable
Continuous variables
Age per 10 y
Total cholesterol per 0.5 mmol/L
HDL cholesterol per 0.1 mmol/L
LDL cholesterol per 0.5 mmol/L
Triglycerides per 0.5 mmol/L
Systolic blood pressure per 10 mm Hg
Diastolic blood pressure per 10 mm Hg
Serum glucose per 1.0 mmol/L
Homocysteine per 1.0 mol/L
Body mass index per 1.0 kg/m2
Creatinine clearance (Cockroft) per 10 mL/min
Dichotomous variables*
Sex (female)
Diabetes mellitus type 2 (present)
Smoking (current smoking)
History of cerebrovascular disease (present)*
History of coronary heart disease (present)*
History of abdominal aortic aneurysm (present)*
HR, Hazard ratio adjusted for age; CI, confidence interval; HDL, high-den
*Reference category in parentheses.were lost to follow-up. Of the remaining 333 (72%) pa-tients, 221 (66%) came for follow-up measurement, and
112 (34%) patients did not participate because of comor-
bidity, lack of time, lack of motivation, and travel distance.
In 8 of the 221 patients, a nonfatal vascular event occurred:
2 had an ischemic stroke, and 6 patients had an MI. A
PAD-related amputation occurred in 12 (5%) of the 221
between baseline and follow-up measurement. Percutane-
ous transluminal angioplasty was performed the first time in
35 (16%) of the 221, and surgical procedures (bypass)
involving the aorta/iliac, iliac, or femoral/popliteal arteries
were performed for the first time in 42 (19%) of the 221
patients.
There were small differences between the baseline char-
acteristics of the participants and those who refused to
participate at follow-up measurement. Participants were
younger (57.1 vs 60.5 years; P  .01), less often had a
history of cerebrovascular disease (7% vs 16%; P .01), had
a lower mean glucose level (6.0 vs 7.0 mmol/L; P  .02),
and had a lower mean systolic blood pressure (144 vs 150
mm Hg; P  .01). The mean follow-up of the participants
was 5.5 years (SD, 1.3 years).
Risk factors at baseline and follow-up. The charac-
teristics of the 221 patients who completed the baseline and
follow-up measurements are given in Table IV. The mean
ABI valuewas 0.85 at baseline and 0.89 at follow-upmeasure-
ment. The mean serum glucose level (6.0 mmol/L) was
comparable at both measurements, but more patients quanti-
fied for the diagnosis diabetesmellitus type 2 at follow-up (8%
vs 16%). The mean levels of total cholesterol (6.0 vs 5.2
mmol/L), LDL cholesterol (4.0 vs 2.9 mmol/L), HDL
cholesterol (1.1 vs 1.4 mmol/L), and triglycerides (2.1 vs 1.8
mmol/L) weremore favorable at follow-up. The percentage
of current smokers had decreased from 59% to 37%. The
for vascular events (n  461)
HR 95% CI P value
1.85 1.48-2.30 .001
0.92 0.84-1.01 .07
0.94 0.89-1.00 .06
0.94 0.85-1.04 .9
1.01 0.94-1.08 .8
1.01 0.91-1.11 .9
1.00 0.81-1.22 .96
1.06 0.98-1.15 .2
1.03 1.02-1.05 .001
1.01 0.96-1.07 .6
0.79 0.69-0.91 .001
0.64 0.40-1.03 .07
1.49 0.89-2.51 .1
1.13 0.98-1.31 .09
1.46 0.85-2.52 .2
2.30 1.51-3.51 .001
1.52 0.76-3.03 .2
poprotein; LDL, low-density lipoprotein.isticsmean systolic and diastolic blood pressure, homocysteine
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mean follow-up of 5.5 years (Table IV).
During this period, the number of risk factors in indi-
vidual patients remained the same in 93 (42%) patients,
decreased in 71 (32%) patients, and increased in 57 (26%)
patients. The decrease in risk factors was mainly caused by
patients who quit smoking (from 59% to 37%; 95%CI,13%
to 31%) and by fewer patients with increased lipid levels
(from 96% to 73%; 95% CI, 29% to 16%; Table V). The
increase in risk factors was caused bymore hypertension (19%;
95% CI, 10%-28%), more obesity (12%; 95% CI, 3%-21%),
and more diabetes mellitus (8%; 95% CI, 2%-14%). Medi-
cation use in all categories increased with time (Table V).
DISCUSSION
In this study, we showed that older age, increased
homocysteine levels, impaired renal function, and a history
of CHD (age adjusted) were related to an increased risk of
future vascular events in patients with PAD. In addition, we
demonstrated that after a mean follow-up of 5.5 years,
mean blood pressure, homocysteine levels, and BMI had
increased, whereas mean lipid levels and the prevalence of
smoking decreased. Furthermore, comparison of risk fac-
tors at baseline and at follow-up showed that risk factors
had increased in 26% of patients (mainly as a result of an
increased prevalence of hypertension, followed by obesity
and diabetes), remained stable in 42% of patients, and
Table IV. Characteristics of patients with symptomatic
peripheral arterial disease at baseline and follow-up
Characteristic
Baseline
(n  221)
Follow-up
(n  221)
Male sex (%) 67 67
Age (y) 57.1  9.9 62.6  10.0
Total cholesterol (mmol/L) 6.0  1.1 5.2  1.2
LDL cholesterol (mmol/L) 4.0  1.0 2.9  1.0
HDL cholesterol (mmol/L) 1.1  0.3 1.4  0.4
Triglycerides (mmol/L) 2.1  1.4 1.8  1.0
Systolic blood pressure (mm Hg) 144  21 152  23
Diastolic blood pressure (mm Hg) 80  10 83  11
Fasting serum glucose (mmol/L) 6.0  1.5 6.0  1.7
Diabetes mellitus type 2* (%) 8 16
Homocysteine (mol/L) 13.9  5.2 14.5  10.5
Body mass index (kg/m2) 25.6  3.8 26.6  4.2
Waist circumference (cm) 95  11 98  12
Current smoking (%) 59 37
Creatinine clearance
(Cockcroft; mL/min)
78  20 82  29
Albuminuria 3.0 mg/mmol (%) 14 25
Ankle brachial pressure index 0.85  0.2 0.89  0.2
Medication use
Antiplatelet agents (%) 47 80
Blood pressure–lowering agents (%) 31 44
Lipid-lowering agents (%) 22 66
ACE inhibitor and/or AIIA (%) 20 35
Folic acid (%) 2 11
HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACE, angio-
tensin-converting enzyme; AIIA, angiotensin II-antagonist.
Data are mean (SD) or %.
*Patients taking glucose-lowering agents.decreased in 32% of the patients.Atherosclerosis is a systemic disease affecting multiple
arteries simultaneously. Treatment of patients with symp-
tomatic PAD requires not only local treatment to decrease
limb-specific symptoms, but also lifestyle changes and treat-
ment of risk factors to decrease the absolute vascular risk.
Despite overwhelming evidence of the benefit of risk reduc-
tion, most risk factors are inadequately managed in patients
with PAD.12,14,19-22 This could have two causes: First,
treating physicians may be not aware of the increased
cardiovascular risk of these patients and are therefore less
keen on starting aggressive risk factor management and the
necessary lifestyle changes.23 Second, patients may be not
aware of the implications of PAD and their prognosis.
Several previous studies reported progression of atheroscle-
rosis in patients with symptomatic PAD, with a high case
fatality of vascular deaths,4,5,24,25 that was not influenced
by the sites of the original symptoms.26 In our study, 108
(23%) of the 461 patients died, and 66 (61%) of 108 of
these deaths were caused by CVD within a mean follow-up
of 5.5 years. In a large database study involving 16,440
patients diagnosed with PAD between 1985 and 1995
without a reported Fontaine classification and with an
average follow-up of 5.9 years, 7973 deaths (48%) were
reported. The numbers of vascular deaths were not pub-
lished.24 In a 10-year prospective follow-up study of 67
patients with diagnosed PAD, 32 deaths (48%) due to all
causes were reported, 22 (69%) of which were caused by
CVD.4 It seems that the number of all-cause deaths and of
deaths associated with vascular disease decreases in time in
PAD patients with a mean age between 60 and 67 years.
In this study, we found that several baseline risk factors
were associated or borderline significantly associated with
an increased risk of future vascular events independently of
classic risk factors. Some predictors, such as sex, age, and
medical history, are not modifiable. Others are potentially
modifiable, and these changed over time. The mean plasma
HDL cholesterol concentration increased by 0.3 mmol/L
during follow-up, the creatinine clearance remained essen-
tially the same, and the plasma homocysteine concentration
increased, although the increase was rather small (0.6
mol/L). The pathophysiological pathway of the effect of
renal function on subsequent events remains unclear. De-
creased renal function may be a reflection of advanced and
diffuse atherosclerosis. However, metabolic changes ac-
companied by renal insufficiency (inflammation and endo-
thelial dysfunction) may contribute to future vascular
events. Homocysteine has been suggested as a risk indicator
of an increased risk of CVD,27 but treatment of homocys-
teine with folic acid or vitamins has not been shown to
prevent future vascular events.28 The two strongest risk
factors for the development of PAD, smoking and diabetes,
were not predictive for subsequent cardiovascular events.
One other study also found that smoking is not a risk factor
for new vascular events in PAD patients,25 whereas other
studies reported a relationship between smoking and clini-
cal progression of PAD.26,29 A possible explanation of the
fact that smoking at baseline was not predictive for future
vascular events in our study could be the reduced risk of a
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stantial percentage of patients who stopped smoking (59%
to 37%). A recent study indicated that diabetes was more
predictive in small-vessel disease than in large-vessel dis-
ease,29 whereas another study showed that diabetes is a
prognostic factor after a nonfatal MI.30 A small number of
patients with diabetes (n 63) at baseline, and, thus, a lack
of power, could be a reason why we did not find diabetes to
be an independent predictor.
Undertreatment of existing risk factors was confirmed
in our study, even though all patients were screened and
treatment advice was given to the treating vascular specialist
and the GP about medical treatment and lifestyle changes.
The prevalence of diabetes mellitus, a major risk factor for
PAD,2 increased during the follow-up period. However,
the prevalence of another strong risk factor, current smok-
ing, decreased, possibly as a result of advice given to the
treating physicians or of the strong public health campaign
against smoking.
In general, medication use was higher at follow-up than
at baseline. We reported earlier that treatment recommen-
dations sent to the treating vascular specialist and GP led to
a marginal increase in medication use compared with usual
care.31 In this study, an increase in the use of antiplatelet
agents was noticed, although 20% of the patients did not
take antiplatelet agents at follow-up, even though these
drugs provide, on average, a 19% relative risk reduction in
major vascular events in patients with arterial disease.8
Angiotensin-converting enzyme inhibitors were taken by
only 20% of the patients at baseline and by 35% at follow-up.
Use of angiotensin-converting enzyme inhibitors reduces the
cardiovascular risk in high-risk patients who are not known to
have a low ejection fraction or heart failure,6 although no
statistically significant benefits were found in the Preven-
tion of Events with Angiotensin-Converting Enzyme Inhi-
bition (PEACE) trial, which included patients with stable
CHD and preserved left ventricular function.32 In addi-
tion, to reduce cardiovascular complications in patients
with PAD,33 there is evidence that statins may also specifi-
Table V. Difference in risk factors and use of drugs betwe
Variable % (n) at baseline % (n) at fo
Hypertension* 51 (113) 70 (15
Hyperlipidemia† 96 (211) 73 (16
Diabetes mellitus‡ 8 (17) 16 (35
Obesity§ 54 (120) 67 (14
Current smoking 59 (130) 37 (82
Antiplatelet agents 47 (99) 79 (16
Blood pressure–lowering drugs 31 (67) 44 (95
Lipid-lowering drugs 22 (47) 66 (13
ACE inhibitor and/or AIIA 20 (43) 35 (75
CI, Confidence interval; ACE, angiotensin-converting enzyme; AIIA, angi
*Systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm
†Total cholesterol 4.5 mmol/L or LDL cholesterol 2.5 mmol/L.
‡Patients taking glucose-lowering agents.
§Body mass index 25 kg/m2.cally limit PAD progression34 and improve pain-free walk-ing distance.35 In our study, lipid-lowering agent use in-
creased from 22% to 66% at follow-up, and this may
contribute to the decrease in prevalence of hyperlipidemia.
Studies such as ours emphasize the need to pay atten-
tion to effective risk factor management because of the
burden of PAD and its complications on patients and
society. Treatment of acute vascular complications by a
doctor and management of risk factors by a nurse practitio-
ner have been shown to initiate behavioral changes and to
help patients to cope with illness and vascular risk. This
approach led to a reduction in vascular risk in patients with
manifestations of CVD within the same study cohort.36
Therefore, spending more time for education about exist-
ing risk factors, medication use, and absolute vascular risk
may result in better treatment of risk factors.
Our study had some limitations. The study population
might be a selected group of patients with symptomatic
PAD referred to an academic center, and only patients who
wished to participate were included. Because the survivors
of our cohort were invited to participate in the follow-up
measurement after amean of 5.5 years, it is possible that less
severely affected, younger patients with PAD participated
in the follow-up measurement. A strength of our study is
that we used data collected from patients with symptomatic
PAD over a long period and examined risk determinants
associated with fatal and nonfatal vascular events.
In conclusion, in patients with symptomatic PAD,
older age, increased homocysteine levels, impaired renal
function, and a history of CHD (age adjusted) were
associated with an increased risk of future vascular
events. The prevalence of most risk factors increased over
a 5.5-year period, except for smoking and hyperlipid-
emia, even though medication use also increased in this
time period.
We gratefully acknowledge the contribution of L. Pe-
rales and H. van de Hoorn (research nurses), M. Edlinger
(data manager), J. Sykes (native speaker of English), and
the SMART study group, the members of which are listed
llow-up and baseline (n  221)
p % Increase (follow-up  baseline) 95% CI P value
19 10 to 28 .001
23 29 to 16 .001
8 2 to 14 .001
12 3 to 21 .001
22 13 to 31 .001
32 24 to 41 .001
13 4 to 22 .001
44 35 to 52 .001
15 7 to 23 .001
n II-antagonist.en fo
llow-u
5)
1)
)
7)
)
7)
)
9)
)
otensi
Hg.in the appendix.
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APPENDIX
Members of the SMART Study Group are as follows: A.
Algra,MD,PhD,Y. van derGraaf,MD,PhD,D.E.Grobbee,for Health Sciences and Primary care; F. L. J. Visseren, MD,
PhD, Department of Vascular Medicine; H. A. Koomans,
MD, PhD, Department of Nephrology; B. C. Eikelboom,
MD, PhD, and F. L. Moll, MD, PhD, Department of Vascu-
lar Surgery; L. J. Kappelle, MD, PhD, Department of Neu-
rology; W. P. T. M. Mali, MD, PhD, Department of Radiol-
ogy; and P. A. Doevendans, MD, PhD, Department ofMD, PhD, andG. E.H.M. Rutten,MD, PhD, Julius Center Cardiology.
